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Introduction
Interleukin-2 (IL2) therapy for cancer has stood the test
of time, with continued widespread use with clinical
complete responses (CR) variably reported at 5%-20%
for advanced malignant melanoma, renal cell carcinoma,
and a range of other cancers. IL-2 is recognized to be
curative with strong durable long-term 5-10-year survi-
vals, usually resulting from CR’s.
Methods
The literature was reviewed for clinical trials using low,
intermediate and high dose IL2 therapy, alone or in com-
bination. A meta-analysis was performed on the data.
Results
At completion, 62 trials were identified as meeting the
inclusion criteria, encompassing 5312 patients treated
using IL2. A complete response rate of 6% across the
entire IL2 treated population was determined. IL2 alone
and in combination, and the dosing was investigated. All
doses and regimens were capable of producing CR’s.
Conclusions
Finally, after over 20 years of use and investigation of
IL2, the mechanisms of action of IL2 as a ‘homeostatic’
cytokine are becoming clearer. The physiological feed-
back of IL2 actions over T-cell effector and regulatory
functions indicate that there is a homeostatic balance,
which is capable of being manipulated by exogenous
(therapeutic) IL-2 towards either net responsiveness or
tolerance. This is underpinned by transient expression
of IL-2 receptor levels on the respective effector or reg-
ulatory populations. In this regard, the timing and fre-
quency of IL2 administration will necessarily determine
the clinical outcome through ‘immune synchronization’.
The way forward is to monitor systemic inflammation,
to determine the optimal time for IL2 dose delivery; and
not to give up on the patient too early because non-
responsiveness can be turned into responsiveness with
repetitive accurate dosing. This phenomenon is just
becoming apparent with other therapies, showing that
the solution to the problem is obtainable by carefully
coordinated and timed therapeutic administration.
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